213 related articles for article (PubMed ID: 21360545)
1. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.
Sakamoto N; Nakagawa M; Tanaka Y; Sekine-Osajima Y; Ueyama M; Kurosaki M; Nishida N; Tamori A; Yuki NS; Itsui Y; Azuma S; Kakinuma S; Hige S; Itoh Y; Tanaka E; Hiasa Y; Izumi N; Tokunaga K; Mizokami M; Watanabe M;
J Med Virol; 2011 May; 83(5):871-8. PubMed ID: 21360545
[TBL] [Abstract][Full Text] [Related]
2. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
[TBL] [Abstract][Full Text] [Related]
3. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
Moghaddam A; Melum E; Reinton N; Ring-Larsen H; Verbaan H; Bjøro K; Dalgard O
Hepatology; 2011 Mar; 53(3):746-54. PubMed ID: 21374656
[TBL] [Abstract][Full Text] [Related]
4. [Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
Xu H; Guo LL; He LL; Chen Y; Liu K; Lei BJ; Lei XZ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):855-9. PubMed ID: 23387213
[TBL] [Abstract][Full Text] [Related]
5. Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy.
Takita M; Hagiwara S; Arizumi T; Hayaishi S; Ueda T; Kitai S; Yada N; Inoue T; Minami Y; Chung H; Ueshima K; Sakurai T; Kudo M
Digestion; 2011; 84 Suppl 1():56-61. PubMed ID: 22156487
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
[TBL] [Abstract][Full Text] [Related]
7. Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene.
Grandi T; da Silva CM; Amaral KM; Picon PD; Costi C; da Fré NN; Fiegenbaum M; Niel C; Rossetti ML
Mem Inst Oswaldo Cruz; 2013 Feb; 108(1):48-53. PubMed ID: 23440114
[TBL] [Abstract][Full Text] [Related]
8. Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.
Yokoyama S; Kawakami Y; Imamura M; Hayes CN; Kohno H; Kohno H; Tsuji K; Aisaka Y; Kira S; Yamashina K; Nonaka M; Takahashi S; Moriya T; Kitamoto M; Aimitsu S; Nakanishi T; Kawakami H; Chayama K
J Gastroenterol Hepatol; 2015 Feb; 30(2):337-44. PubMed ID: 25091289
[TBL] [Abstract][Full Text] [Related]
9. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
Tahata Y; Hiramatsu N; Oze T; Urabe A; Morishita N; Yamada R; Yakushijin T; Hosui A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Yamada Y; Inada M; Katayama K; Tamura S; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
J Med Virol; 2016 Oct; 88(10):1776-84. PubMed ID: 26991414
[TBL] [Abstract][Full Text] [Related]
10. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Taniai H; Okada K; Kainuma M; Hayashi J
J Hepatol; 2012 Sep; 57(3):534-40. PubMed ID: 22613000
[TBL] [Abstract][Full Text] [Related]
12. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
[TBL] [Abstract][Full Text] [Related]
13. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
14. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453
[TBL] [Abstract][Full Text] [Related]
15. [Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].
Liu B; Cai WP; Hu FY; Xu M; Lan Y; Tang XP
Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):829-33. PubMed ID: 24331692
[TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA
J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783
[TBL] [Abstract][Full Text] [Related]
17. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
[TBL] [Abstract][Full Text] [Related]
18. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.
Di Marco V; Calvaruso V; Grimaudo S; Ferraro D; Pipitone RM; Di Stefano R; Craxì A
J Viral Hepat; 2013 Feb; 20(2):113-21. PubMed ID: 23301546
[TBL] [Abstract][Full Text] [Related]
19. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
20. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.
Kim SR; El-Shamy A; Imoto S; Kim KI; Ide YH; Deng L; Shoji I; Tanaka Y; Hasegawa Y; Ota M; Hotta H
J Gastroenterol; 2012 Oct; 47(10):1143-51. PubMed ID: 22441534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
